Noshingjian Obutini has been approved by the FDA to conduct a phase II study on the treatment of MS

This will be a randomized, double-blind, placebo-controlled International Multi-Center Clinical Phase II study for patients with relapsed remission-relieved multiple sclerosis (RRMS), which will be conducted in the United States and several European countries and will recruit 160 patients.
MS is an autoimmune central nervous system disease in which the patient's immune system abnormally attacks the myelin around nerve cells, causing inflammation and tissue damage that disrupts the normal functioning of the brain, optic nerve and spinal cord.
can cause muscle weakness, fatigue and visual impairment, and ultimately disability.
most MS patients begin to experience their first symptoms in their 20s and 40s, making the disease a major cause of non-traumatic disability in young people.
more than 2.8 million people worldwide now suffer from multiple sclerosis, according to the International Federation of Multiple Sclerosis (MSIF).
ms market is expected to reach $23 billion in 2018 and is expected to reach $48.9 billion by 2030, according to analysis by Frost Sullivan.
BTK, as a key kinase in the signaling path of B cells, is important for the development and function of Immune cells involved in MS pathological processes such as B lymphocytes, macrophages, and small glials.
, BTK inhibitors are expected to offer novel treatment options for the treatment of autoimmune diseases such as MS.
is a highly targeted and selective new BTK inhibitor for the treatment of B-cell lymphoma and autoimmune diseases.
Currently, Aubudinib is conducting multi-center, multi-adaptive clinical trials in China and the United States to study its efficacy and safety as a single and combined drug, and clinical results show good safety and efficacy.
: s1. Source: MSIF Official Website Source: Frost and Sullivan Analysis Note: The original text has been deleted